For better monitoring of tumor molecular changes, liquid biopsy is emerging as a more convenient and potentially lower-cost alternative to tissue biopsy. Liquid biopsy detects genetic aberrations in circulating tumor cells and deoxyribonucleic acid from apoptotic and necrotic tumor cells.
Ying Pan (email@example.com) is a senior scientist at the Stanford University School of Medicine, where she had her postdoctoral fellowship. She received her Ph.D. degree in virology from Wuhan University, China, and her bachelor’s degree in biochemical engineering from Hubei University, China. She is interested in molecular diagnostics for cancer and infectious disease.